文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

二肽基肽酶-4抑制剂与2型糖尿病患者胆囊或胆道疾病:随机对照试验的系统评价及配对与网状Meta分析

Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2022-06-28

该系统评价与配对及网状Meta分析纳入82项随机对照试验共104 833例2型糖尿病患者,评估二肽基肽酶-4抑制剂与胆囊或胆道疾病的关联。结果显示,与安慰剂或非肠促胰岛素药物相比,二肽基肽酶-4抑制剂显著增加胆囊或胆道疾病复合终点(OR 1.22,95%CI 1.04-1.43)和胆囊炎(OR 1.43,95%CI 1.14-1.79)风险,但与胆石症和胆道疾病风险无关。网状Meta分析(184项试验)中,二肽基肽酶-4抑制剂较钠-葡萄糖共转运蛋白-2抑制剂增加复合终点和胆囊炎风险,但与胰高血糖素样肽-1受体激动剂相比无显著差异。

要点

  • 二肽基肽酶-4抑制剂与胆囊或胆道疾病复合终点风险升高相关(OR 1.22,95%CI 1.04-1.43)。
  • 二肽基肽酶-4抑制剂与胆囊炎风险升高相关(OR 1.43,95%CI 1.14-1.79)。
  • 该关联趋向见于二肽基肽酶-4抑制剂治疗时间较长的患者。

核心结论

  • 二肽基肽酶-4抑制剂增加随机对照试验中胆囊炎的风险,尤其是在治疗时间较长时,临床实践中医生需对此多加关注。

研究设计与样本

  • 系统评价与配对及网状Meta分析,检索PubMed、EMBASE、Web of Science和CENTRAL自建库至2021年7月31日。
  • 纳入成人2型糖尿病患者接受二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂或钠-葡萄糖共转运蛋白-2抑制剂对比安慰剂或其他降糖药物的随机对照试验。
  • 配对Meta分析纳入82项随机对照试验共104 833例参与者;网状Meta分析纳入184项试验。
  • 两名评价者独立提取数据并评估研究质量,采用GRADE框架评估每个结局的证据质量。

主要发现

  • 与安慰剂或非肠促胰岛素药物相比,二肽基肽酶-4抑制剂与胆囊或胆道疾病复合终点风险升高显著相关(OR 1.22,95%CI 1.04-1.43;每10 000人年多11例事件,95%CI 2-21)。
  • 与安慰剂或非肠促胰岛素药物相比,二肽基肽酶-4抑制剂与胆囊炎风险升高显著相关(OR 1.43,95%CI 1.14-1.79;每10 000人年多15例事件,95%CI 5-27)。
  • 与安慰剂或非肠促胰岛素药物相比,二肽基肽酶-4抑制剂与胆石症和胆道疾病风险无显著关联。
  • 该关联趋向见于二肽基肽酶-4抑制剂治疗时间较长的患者。
  • 网状Meta分析中,与钠-葡萄糖共转运蛋白-2抑制剂相比,二肽基肽酶-4抑制剂增加胆囊或胆道疾病复合终点和胆囊炎风险;与胰高血糖素样肽-1受体激动剂相比无显著差异。

临床怎么用

  • 原文结论指出二肽基肽酶-4抑制剂增加胆囊炎风险,尤其在治疗时间较长时,临床实践中医生需对此多加关注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between dipeptidyl peptidase-4 inhibitors and gallbladder or biliary diseases. DESIGN: Systematic review and pairwise and network meta-analysis. DATA SOURCES: PubMed, EMBASE, Web of Science, and CENTRAL from inception until 31 July 2021. ELIGIBILITY CRITERIA: Randomised controlled trials of adult patients with type 2 diabetes who received dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors compared with placebo or other antidiabetes drugs. MAIN OUTCOME MEASURES: Composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases. DATA EXTRACTION AND DATA SYNTHESIS: Two reviewers independently extracted the data and assessed the quality of the studies. The quality of the evidence for each outcome was assessed using the Grading of Recommendations, Assessment, Development and Evaluations framework (GRADE) approach. The meta-analysis used pooled odds ratios and 95% confidence intervals. RESULTS: A total of 82 randomised controlled trials with 104 833 participants were included in the pairwise meta-analysis. Compared with placebo or non-incretin drugs, dipeptidyl peptidase-4 inhibitors were significantly associated with an increased risk of the composite of gallbladder or biliary diseases (odds ratio 1.22 (95%confidence interval 1.04 to 1.43); risk difference 11 (2 to 21) more events per 10 000 person years) and cholecystitis (odds ratio 1.43 (1.14 to 1.79); risk difference 15 (5 to 27) more events per 10 000 person years) but not with the risk of cholelithiasis and biliary diseases. The associations tended to be observed in patients with a longer duration of dipeptidyl peptidase-4 inhibitor treatment. In the network meta-analysis of 184 trials, dipeptidyl peptidase-4 inhibitors increased the risk of the composite of gallbladder or biliary diseases and cholecystitis compared with sodium-glucose cotransporter-2 inhibitors but not compared with glucagon-like peptide-1 receptor agonists. CONCLUSIONS: Dipeptidyl peptidase-4 inhibitors increased the risk of cholecystitis in randomised controlled trials, especially with a longer treatment duration, which requires more attention from physicians in clinical practice. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021271647.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ. 2022. PMID: 35764326. doi:10.1136/bmj-2021-068882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。